Thrombosis risk and survival in cancer patients with elevated C-reactive protein

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 1, 2011, Pages 57-63

  Kanz, R ^a   Vukovich, T ^b   Vormittag, R ^a   Dunkler, D ^c   Ay, C ^a   Thaler, J ^a   Haselbock J ^a   Scheithauer, W ^d   Zielinski, C ^d   Pabinger, I ^a  

^a Clinical Division of Haematology and Haemostaseology   (Austria)

^b Medical and Chemical Laboratory Diagnostics   (Austria)

^c Section of Clinical Biometrics   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C reactive protein; Cancer; Mortality; SP selectin; Survival; Venous thromboembolism

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR RISK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SOLID TUMOR; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

AGED; AUSTRIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; NEPHELOMETRY AND TURBIDIMETRY; P-SELECTIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; UP-REGULATION; VENOUS THROMBOEMBOLISM;

EID: 78650952222     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04069.x     Document Type: Article

References (32)

1. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-505.
2. Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation 2009; 32: 169-75.
3. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009; 32: 471-82.
4. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279: 48487-90.
5. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.
6. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-61.
7. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-9.
8. Vormittag R, Funk M, Mannhalter C, Schonauer V, Vukovich T, Minar E, Bialonczyk C, Hirschl M, Pabinger I. C-reactive protein 3' UTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis 2006; 188: 406-11.
9. Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, Scheulen ME. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297-303.
10. Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 2007; 100: 269-73.
11. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998; 31: 351-7.
12. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009; 27: 3437-44.
13. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27: 2217-24.
14. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-8.
15. Ferroni P, Roselli M, Martini F, D'Alessandro R, Mariotti S, Basili S, Spila A, Aloe S, Palmirotta R, Maggini A, Del Monte G, Mancini R, Graziano F, Cosimelli M, Guadagni F. Prognostic value of soluble P-selectin levels in colorectal cancer. Int J Cancer 2004; 111: 404-8.
16. Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007; 16: 1155-9.
17. Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 2007; 5: 51.
18. Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008; 102: 756-61.
19. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005; 11: 1639-43.
20. Chung YC, Chang YF. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 2003; 15: 369-73.
21. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-9.
22. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim HJ. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009; 9: 155.
23. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008; 112: 2377-83.
24. Six L, Polterauer S, Grimm C, Seebacher V, Tempfer C, Heinze G, Joura E, Reinthaller A, Hefler LA. C-reactive protein serum levels are closely associated with lymph node status, but not with prognosis in patients with vulvar cancer. Eur J Obstet Gynecol Reprod Biol 2008; 137: 217-21.
25. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008; 14: 710-4.
26. Suh SY, Ahn HY. A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer 2007; 15: 613-20.
27. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, Wagner OF, Endler G. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 2008; 54: 343-9.
28. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
29. Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2009; 203: 67-74.
30. Cirillo P, Golino P, Calabro P, Cali G, Ragni M, De Rosa S, Cimmino G, Pacileo M, De Palma R, Forte L, Gargiulo A, Corigliano FG, Angri V, Spagnuolo R, Nitsch L, Chiariello M. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005; 68: 47-55.
31. Ji SR, Ma L, Bai CJ, Shi JM, Li HY, Potempa LA, Filep JG, Zhao J, Wu Y. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J 2009; 23: 1806-16.
32. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-46.